PD-128,907 is a drug used in scientific research which acts as a potent and selective agonist for the dopamine D2 and D3 receptors.[1] It is used for studying the role of these receptors in the brain, in roles such as inhibitory autoreceptors that act to limit further dopamine release,[2] as well as release of other neurotransmitters.[3] In animal studies, it has been shown to reduce toxicity from cocaine overdose.[4][5]
Quick Facts Identifiers, CAS Number ...
PD-128,907 |
|
(4aR,10bR)-3,4a,4,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
ChEMBL | |
---|
CompTox Dashboard (EPA) | |
---|
|
Formula | C14H19NO3 |
---|
Molar mass | 249.310 g·mol−1 |
---|
3D model (JSmol) | |
---|
CCCN1CCO[C@H]2[C@H]1COC3=C2C=C(C=C3)O
|
InChI=1S/C14H19NO3/c1-2-5-15-9-17-7-12-11-6-10(16)3-4-14(11)18-8-13(12)15/h3-4,6,12-13,16H,2,5,7-9H2,1H3/t12-,13-/m1/s1 NKey:ZFSOBPVEIKTNQS-CHWSQXEVSA-N N
|
NY (what is this?) (verify) |
Close
DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, et al. (January 1990). "Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers". Journal of Medicinal Chemistry. 33 (1): 445–50. doi:10.1021/jm00163a068. PMID 1967318.
Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, et al. (March 2004). "Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 957–64. doi:10.1124/jpet.103.059980. PMID 14711932.
Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M (September 2008). "The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors". The Journal of Pharmacology and Experimental Therapeutics. 326 (3): 930–8. doi:10.1124/jpet.108.139212. PMID 18566292.